New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 9, 2014
09:13 EDTBP, KKR, SDRL, SIMG, LO, TCS, COH, LXRX, SLXP, AVAV, RAI, AAL, CELG, GRMN, MSM, BOBE, GIMOOn The Fly: Pre-market Movers
HIGHER: American Airlines (AAL), up 5.5% after reporting its June traffic rose 1%, forecasting its 2014 total system capacity to be up 3% from last year... AeroVironment (AVAV), up 5.5% after reporting better than expected Q4 earnings results... Reynolds American (RAI), up 1.3% after Daily Mail reported that British American Tobacco (BTI) is rumored to be near a deal to buy out the stake in Reynolds it does not already own, which would prevent a Reynolds takeover of Lorillard (LO). Lorillard shares are down 1.4% in pre-market trade following the report... Lexicon (LXRX), up 11.5% after announcing JDRF, the world's largest non-profit supporter of type 1 diabetes research, will provide funding to support a Phase 2 trial to evaluate the efficacy and safety of LX4211... Seadrill (SDRL), up 3% after cancelling contemplated convertible bond issuance... KKR (KKR), up 1.3% after upgraded to Outperform at Credit Suisse. DOWN AFTER EARNINGS: Container Store (TCS), down 15%... Bob Evans (BOBE), down 1.2%... MSC Industrial (MSM), down 3%. ALSO LOWER: Gigamon (GIMO), down 32% following downgrades at five firms after the company lowered its Q2 revenue guidance... Garmin (GRMN), down 2.7% following downgrade at Pacific Crest... Silicon Image (SIMG), down 11% after cutting second quarter guidance... Salix (SLXP), down 4% after announcing deal to combine with Cosmo Technologies... Celgene (CELG), down 1.5% after OTEZLA did not achieve primary endpoint in Phase III trial... Coach (COH), down 0.7% following downgrade at Buckingham... BP (BP), down 1% after downgraded at Deutsche Bank.
News For AAL;TCS;GIMO;RAI;LO;BOBE;AVAV;SIMG;MSM;SLXP;SDRL;GRMN;LXRX;KKR;CELG;COH;BP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | all recent news | >>
December 9, 2014
10:23 EDTCOHOn The Fly: Analyst Initiation Summary
Subscribe for More Information
08:39 EDTBPBP to close U.S. cellulosic operations, Bloomberg reports
Subscribe for More Information
08:34 EDTCELGCelgene price target raised to $130 from $102 at Argus
Argus hiked its price target on Celgene as the firm thinks the company posted solid Q3 results, while it is continuing to make progress in its pipeline. Argus keeps a Buy rating on the shares.
08:28 EDTCELGCelgene price target raised to $130 from $112 at UBS
Subscribe for More Information
07:44 EDTCELGAmerican Association for Cancer Research to hold a symposium
Subscribe for More Information
07:05 EDTCOHCoach initiated with an Equal Weight at Stephens
Subscribe for More Information
05:46 EDTCELGCelgene presents POMALYST/IMNOVID Phase IIIb study results at ASH meeting
Celgene announced that results from the STRATUS trial, a single-arm phase IIIb study of pomalidomide plus low-dose dexamethasone in patients with relapsed and refractory multiple myeloma were presented at the 56th American Society of Hematology annual meeting. Pomalidomide is marketed as POMALYST in the United States and IMNOVID in the European Union. In the study, 599 patients with refractory, or relapsed and refractory, disease who had previously failed lenalidomide and bortezomib had been enrolled at the time of the data cutoff. The primary endpoint was safety, and key secondary endpoints included pomalidomide exposure, overall response rate, or ORR, duration of response, or DOR, progression-free survival, or PFS, overall survival, or OS, and cytogenetic analyses. Patients had a median five prior therapies. All patients received thromboprophylaxis with low-dose aspirin, low-molecular-weight heparin, or equivalent. At a median follow-up of 6.8 months with a median four cycles received, the median PFS and OS were 4.2 months and 11.9 months, respectively. The ORR was 35%, with 8% of patients achieving at least a very good partial response, or VGPR. The median DOR was 6.8 months. In patients refractory to prior lenalidomide or lenalidomide and bortezomib, similar PFS, OS, and ORR were achieved.
05:22 EDTCELGCelgene reports REVLIMID study data suggests improved response rates, PFS, OS
Subscribe for More Information
05:17 EDTCELGCelgene reports Vidaza Phase III study shows doubled overall survival times
Subscribe for More Information
December 8, 2014
14:06 EDTCELGCelgene reports luspatercept, sotatercept increased hemoglobin levels in trials
Subscribe for More Information
13:54 EDTCELGCelgene announces results from phase lll Revlimid study
Subscribe for More Information
10:53 EDTBPBP to continue advocating for probe of suspicious, implausible spill claims
Subscribe for More Information
10:11 EDTBPBP's plea to review Deepwater Horizon settlement rejected, WSJ reports
Subscribe for More Information
08:25 EDTRAIReynolds American CFO change not related to negative event, says RBC Capital
After Reynolds' CFO retired, RBC Capital says that the CFO's retirement appears to have been planned ahead of time and does not indicate any problems at the company. The firm keeps a Top Pick rating on the shares.
08:04 EDTAALAmerican Airlines reports November revenue passenger miles down 0.5% to 16.2B
American Airlines's total revenue passenger miles for the month were 16.2B, down 0.5% versus November 2013. Total capacity was 20.8B available seat miles, up 0.9% versus November 2013. Total passenger load factor was 77.7% for the month of November, down 1.1 points versus November 2013. The company expects its fourth quarter consolidated passenger revenue per available seat mile to be approximately down one percent to up 1%. In addition, the company continues to expect its fourth quarter pretax margin excluding special charges to be approximately 10%-12%.
07:53 EDTBPClimate for Exxon E&P acquisition improved by falling prices, WSJ says
Subscribe for More Information
07:36 EDTCELGAgios announces Celgene to extend discovery phase of collaboration to April 2016
Agios Pharmaceuticals (AGIO) announced that Celgene (CELG) has elected to extend the period of its exclusivity for an additional year to April 2016 under the global strategic collaboration agreement. The two companies have been working together since April 2010 to discover, develop and commercialize disease-altering therapies in oncology arising from Agios' cancer metabolism research platform. The terms of the collaboration extension are consistent with previously agreed upon financial terms. As a result of the extension, Celgene will maintain its exclusive option to drug candidates that emerge from Agios' cancer metabolism research platform through April 2016. Agios will receive a $20M payment. Following this extension, the discovery portion of the collaboration will expire on April 14, 2016. Under the terms of the original agreement announced in April 2010, Agios leads research, preclinical and early development efforts through Phase 1, while Celgene receives an option to obtain exclusive rights either upon IND acceptance or at the end of Phase 1, to further development and commercialize medicines emerging from Agios' cancer metabolism research. Celgene would lead and fund global development and commercialization of some of these drugs, and Agios would retain development and commercialization rights for certain drugs in the United States. On all programs, Agios is eligible to receive up to $120M in milestone-based payments as well as royalties on any sales.
07:17 EDTCELGCelgene price target raised to $131 from $120 at Cantor
Subscribe for More Information
06:09 EDTBPBP to cut hundreds of U.K. jobs this week, Guardian reports
Subscribe for More Information
05:35 EDTCELGCelgene REVLIMID, low-dose dexamethasone increased PFS
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | 6 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use